Side effect . | Patients (n) . | Events (n) . | Absolute 5-year risk (%) . | Hazard ratio (95% CI) . | P value . | |||
---|---|---|---|---|---|---|---|---|
TZD . | SU . | TZD . | SU . | TZD . | SU . | (TZD vs. SU) . | ||
Nonobese males | ||||||||
Edema (moderate/severe) | 607 | 620 | 13 | 4 | 3 | 1 | 3.57 (1.16–10.94) | 0.03 |
Fracture (all) | 613 | 623 | 26 | 18 | 7 | 4 | 1.59 (0.87–2.89) | 0.16 |
Hypoglycemia (moderate/severe) | 613 | 623 | 14 | 90 | 3 | 16 | 0.15 (0.09–0.27) | <0.001 |
Obese males | ||||||||
Edema (moderate/severe) | 740 | 719 | 37 | 16 | 7 | 3 | 2.45 (1.34–4.47) | <0.01 |
Fracture (all) | 763 | 743 | 30 | 28 | 6 | 5 | 1.02 (0.61–1.71) | 0.94 |
Hypoglycemia (moderate/severe) | 763 | 743 | 13 | 70 | 2 | 11 | 0.17 (0.09–0.31) | <0.001 |
Nonobese females | ||||||||
Edema (moderate/severe) | 340 | 293 | 13 | 5 | 5 | 2 | 2.10 (0.75–5.89) | 0.16 |
Fracture (all) | 345 | 301 | 31 | 8 | 14 | 3 | 3.15 (1.45–6.87) | <0.01 |
Hypoglycemia (moderate/severe) | 345 | 301 | 10 | 44 | 4 | 17 | 0.17 (0.09–0.35) | <0.001 |
Obese females | ||||||||
Edema (moderate/severe) | 749 | 746 | 60 | 25 | 10 | 5 | 2.16 (1.35–3.45) | <0.01 |
Fracture (all) | 786 | 773 | 77 | 33 | 14 | 6 | 2.14 (1.42–3.23) | <0.001 |
Hypoglycemia (moderate/severe) | 786 | 773 | 18 | 83 | 3 | 13 | 0.19 (0.11–0.31) | <0.001 |
Side effect . | Patients (n) . | Events (n) . | Absolute 5-year risk (%) . | Hazard ratio (95% CI) . | P value . | |||
---|---|---|---|---|---|---|---|---|
TZD . | SU . | TZD . | SU . | TZD . | SU . | (TZD vs. SU) . | ||
Nonobese males | ||||||||
Edema (moderate/severe) | 607 | 620 | 13 | 4 | 3 | 1 | 3.57 (1.16–10.94) | 0.03 |
Fracture (all) | 613 | 623 | 26 | 18 | 7 | 4 | 1.59 (0.87–2.89) | 0.16 |
Hypoglycemia (moderate/severe) | 613 | 623 | 14 | 90 | 3 | 16 | 0.15 (0.09–0.27) | <0.001 |
Obese males | ||||||||
Edema (moderate/severe) | 740 | 719 | 37 | 16 | 7 | 3 | 2.45 (1.34–4.47) | <0.01 |
Fracture (all) | 763 | 743 | 30 | 28 | 6 | 5 | 1.02 (0.61–1.71) | 0.94 |
Hypoglycemia (moderate/severe) | 763 | 743 | 13 | 70 | 2 | 11 | 0.17 (0.09–0.31) | <0.001 |
Nonobese females | ||||||||
Edema (moderate/severe) | 340 | 293 | 13 | 5 | 5 | 2 | 2.10 (0.75–5.89) | 0.16 |
Fracture (all) | 345 | 301 | 31 | 8 | 14 | 3 | 3.15 (1.45–6.87) | <0.01 |
Hypoglycemia (moderate/severe) | 345 | 301 | 10 | 44 | 4 | 17 | 0.17 (0.09–0.35) | <0.001 |
Obese females | ||||||||
Edema (moderate/severe) | 749 | 746 | 60 | 25 | 10 | 5 | 2.16 (1.35–3.45) | <0.01 |
Fracture (all) | 786 | 773 | 77 | 33 | 14 | 6 | 2.14 (1.42–3.23) | <0.001 |
Hypoglycemia (moderate/severe) | 786 | 773 | 18 | 83 | 3 | 13 | 0.19 (0.11–0.31) | <0.001 |
SU, sulfonylureas; TZD, thiazolidinediones.